Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Metastatic Merkel cell carcinoma

Successful treatment with immunotherapy

    • Congress Reports
    • Oncology
    • Partner Content
    • RX
  • 4 minute read

Chemotherapy (ChT) has always been the standard of care for the treatment of metastatic Merkel cell carcinoma (mMCC), but response rates are often not sustained [1, 2]. Bavencio® (avelumab) is the first and only anti-PD-L1 immunotherapy approved in Switzerland for patients with mMCC and is convincing in both the first (1L) and subsequent lines (2L+) with a sustained response and significant survival benefit for patients [2-6]. Current data also confirm its effectiveness in a real clinical context [7-9].

Merkel cell carcinoma (MCC) is a rare disease, but its incidence is increasing [10, 11]. Patients with metastatic disease in particular have a poor prognosis and less than 18% survive for more than 5 years [1, 12]. Bavencio® (avelumab) is an effective immunotherapy in this setting as an alternative to ChT [3, 4]. This article gives you an overview of the most important study results on avelumab in 1L and 2L+ and also summarizes new real-world data presented at the ESMO Congress in October 2023 [1, 2, 5-9].

Sustained response and survival benefit with avelumab

The 1L efficacy of avelumab was tested in a cohort of the phase 2 JAVELIN Merkel 200 study, which included 116 patients with previously untreated mMCC [6]. After a median follow-up of 54.3 months (range: 48.0 – 69.7), the median overall survival (mOS) was 20.3 months (95% CI: 12.4 – 42.0), with a 4-year OS rate of 38.0% (95% CI: 29.0 – 47.0) [6]. The efficacy of avelumab in 2L+ was tested in 88 patients whose disease had progressed after one or more previous lines of ChT [1, 5]. After a median follow-up of 65.1 months (range: 60.8 – 74.1), the mOS was 12.6 months (95% CI: 7.5 – 17.1) with a 5-year OS rate of 26% (95% CI: 17 – 36) [5]. In addition, avelumab showed a low rate of higher grade treatment-related adverse events (TRAEs) and there were no treatment-related deaths in either 1L or 2L+ [2, 5].

Real-world data confirm efficacy in 1L and 2L+

In a prospective German registry study, 100 patients with non-resectable stage III or IV mMCC in 1L were treated with avelumab [7]. After a follow-up of 28.8 months (95% CI: 20.5 – 32.5), the mOS was not reached in either group. The mPFS was 15.6 months (95% CI: 5.6 – NE) and 7.3 months (95% CI: 3.0 – 13.7) for stage III and stage IV mMCC, respectively [7]. In another registry study from England, the mOS of patients with stage III or IV mMCC treated with avelumab or another 1L treatment was compared [8]. With an mOS of 37.8 (95% CI: 12.9 – NE) vs. 13.0 (95% CI: 8.3 – 19.6) months for stage III and 19.9 (95% CI: 5.0 – NE) vs. 7.2 (95% CI: 5.9 – 9.1) months for stage IV, treatment with avelumab proved to be superior compared to other 1L therapies (Fig. 1) [8]. Most recently, a retrospective study from France included 180 patients with mMCC who were treated with avelumab in 2L+. After a median follow-up of 13.1 months, an mOS of 14.6 months (95% CI: 9.9 – 21.3) was recorded from the start of treatment [9].

Conclusion

Overall, both 1L and 2L+ treatment with avelumab offer significant survival benefits for mMCC patients [5, 6]. At the same time, low rates of higher-grade TRAE were observed [2, 5]. Real-world data from several cohorts confirm the survival benefit of avelumab in 1L and 2L+ and thus confirm the clinical results from the JAVELIN Merkel 200 study [2, 5, 7-9].

Figure 1) Overall survival (OS) of patients with stage III or IV mMCC from the start of 1L therapy with avelumab (dark blue) or other 1L therapies (95.5% of which ChT, turquoise).
Adapted from Knott et al. 2023 [8].

Abbreviations

ESMO = European Society for Medical Oncology; CI = confidence interval; PD-L1 = programmed death-ligand 1

The BAVENCIO® brief technical information.

CH-AVE-00074 01/2024

With the financial support of Merck (Schweiz) AG.

Literature

1 D’Angelo, S.P., et al, Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer, 2020. 8(1).
2 D’Angelo, S.P., et al, First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer, 2021. 9(7).
3. information for healthcare professionals BAVENCIO® (avelumab) . www.swissmedicinfo.ch , current status.
4 Becker, J.C., et al, S2k guideline – Merkel cell carcinoma – Update 2022, J Dtsch Dermatol Ges, 2023. 21(3): p. 305-317.
5 D’Angelo, S.P., et al, Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after > 5 years of follow-up. ESMO Open, 2021. 6(6): p. 100290.
6 D’Angelo, S.P., et al, 604 First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial. Journal for ImmunoTherapy of Cancer, 2022. 10(Suppl 2): p. A633-A633.
7 Becker JC, et al. Clinical characteristics and survival of patients with advanced Merkel cell carcinoma (MCC) treated with avelumab: Analysis of a prospective German MCC registry (MCC TRIM). Presentation #1145P. Presented at ESMO Congress October 20-24, 2023.
8 Knott C, et al. First-line treatment (tx) patterns and overall survival (OS) of patients (pts) with advanced Merkel cell carcinoma (aMCC) in England from 2013-2022: Results of a nationwide observational cohort study. Presentation #1147P. Presented at ESMO Congress October 20-24, 2023.
9 Blom A, et al. Avelumab as second-line or later (2L+) treatment (tx) in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Real-world tx patterns in France. Presentation #1148P. Presented at ESMO Congress October 20-24, 2023.
10 Paulson, K.G., et al, Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. J Am Acad Dermatol, 2018. 78(3): p. 457-463.e2.
11 Villani, A., et al, Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies. Dermatol Ther (Heidelberg), 2019. 9(2): p. 209-222.
12 Lemos, B.D., et al, Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol, 2010. 63(5): p. 751-61.

The references are available on request.


Related Topics
  • Congress
  • Oncology
Previous Article
  • Uveal melanoma

Development of a CAR T-cell therapy for uveal melanoma

  • CME continuing education
  • Dermatology and venereology
  • Oncology
  • Ophthalmology
  • RX
  • Studies
View Post
Next Article
  • Psychiatry

TDM, drug therapy safety and pharmacovigilance

  • Education
  • Pharmacology and toxicology
  • Psychiatry and psychotherapy
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 12 min
  • Evidence, effectiveness and practical implications

Medicinal plants for allergic rhinitis

    • RX
    • Allergology and clinical immunology
    • Education
    • General Internal Medicine
    • ORL
    • Pharmaceutical medicine
    • Phytotherapy
    • Studies
View Post
  • 15 min
  • Current status and future prospects

Cell and gene therapies in modern cardiology

    • Cardiology
    • Education
    • Genetics
    • RX
    • Studies
View Post
  • 14 min
  • Patient-oriented recommendations for action

Effect of heat on diabetes technology

    • RX
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Prevention and health care
    • Studies
View Post
  • 19 min
  • Cardiovascular risk and obesity

Pathomechanisms, secondary prevention and treatment options

    • RX
    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • Nutrition
    • Sports Medicine
    • Studies
    • Training with partner
View Post
  • 6 min
  • Ventricular arrhythmias

Indication for ICD or WCD?

    • RX
    • Cardiology
    • Congress Reports
    • General Internal Medicine
    • Studies
View Post
  • 3 min
  • Early breast cancer

Overweight and obesity worsen the prognosis

    • Congress Reports
    • Gynecology
    • Oncology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 8 min
  • Psoriasis treatment with biologics

What are the latest trends?

    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • Rheumatology
    • RX
    • Studies
View Post
  • 4 min
  • Flu vaccination for older people

Benefit of the high-dose influenza vaccine

    • Congress Reports
    • General Internal Medicine
    • Geriatrics
    • Infectiology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Pathomechanisms, secondary prevention and treatment options
  • 2
    Effect of heat on diabetes technology
  • 3
    Improved quality of care aims for satisfied patients
  • 4
    Dr. ChatGPT: Large language models in everyday clinical practice
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.